We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    Rebastinib

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02824575
Recruitment Status : Terminated (Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are terminating early.)
First Posted : July 6, 2016
Last Update Posted : April 4, 2022
Deciphera Pharmaceuticals LLC
Albert Einstein College of Medicine
Information provided by (Responsible Party):
Jesus Anampa Mesias, Montefiore Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : December 27, 2021
Actual Study Completion Date : December 27, 2021